FDMT Accumulated Other Comprehensive Income from 2010 to 2024
| FDMT Stock | USD 7.50 0.12 1.57% |
Accumulated Other Comprehensive Income | First Reported 2010-12-31 | Previous Quarter 16 K | Current Value 16.8 K | Quarterly Volatility 77 M |
Check 4D Molecular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 4D Molecular's main balance sheet or income statement drivers, such as Net Interest Income of 9.6 M, Interest Income of 9.6 M or Depreciation And Amortization of 4.2 M, as well as many indicators such as Price To Sales Ratio of 36.34, Dividend Yield of 0.0 or PTB Ratio of 2.7. FDMT financial statements analysis is a perfect complement when working with 4D Molecular Valuation or Volatility modules.
FDMT | Accumulated Other Comprehensive Income |
Latest 4D Molecular's Accumulated Other Comprehensive Income Growth Pattern
Below is the plot of the Accumulated Other Comprehensive Income of 4D Molecular Therapeutics over the last few years. It is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. 4D Molecular's Accumulated Other Comprehensive Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 4D Molecular's overall financial position and show how it may be relating to other accounts over time.
| Accumulated Other Comprehensive Income | 10 Years Trend |
|
Accumulated Other Comprehensive Income |
| Timeline |
FDMT Accumulated Other Comprehensive Income Regression Statistics
| Arithmetic Mean | (26,817,413) | |
| Coefficient Of Variation | (287.05) | |
| Mean Deviation | 45,023,490 | |
| Median | (964,000) | |
| Standard Deviation | 76,980,431 | |
| Sample Variance | 5926T | |
| Range | 288.3M | |
| R-Value | (0.22) | |
| Mean Square Error | 6077.2T | |
| R-Squared | 0.05 | |
| Significance | 0.43 | |
| Slope | (3,760,969) | |
| Total Sum of Squares | 82963.8T |
FDMT Accumulated Other Comprehensive Income History
About 4D Molecular Financial Statements
4D Molecular shareholders use historical fundamental indicators, such as Accumulated Other Comprehensive Income, to determine how well the company is positioned to perform in the future. Although 4D Molecular investors may analyze each financial statement separately, they are all interrelated. The changes in 4D Molecular's assets and liabilities, for example, are also reflected in the revenues and expenses on on 4D Molecular's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 16 K | 16.8 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.